CBI Services

CBI Services was a discovery-phase contract research organization (CRO) and a primary business unit of Commonwealth Biotechnologies, Inc. (CBI). Based in Richmond, Virginia, the company specialized in providing a comprehensive suite of life science solutions, including biodefense contracting, protein characterization, and GLP-compliant laboratory support for clinical trials. A notable achievement of the company was the development of HepArrest, a proprietary heparin antagonist designed to safely reverse anticoagulation in surgical settings. In 2009, as part of a strategic restructuring, the assets of CBI Services were sold to Bostwick Laboratories for over $1 million plus future royalties. During its peak, the company maintained significant partnerships with global pharmaceutical firms and government agencies, positioning itself as a key player in the preclinical outsourcing market. Its legacy continues through the various technologies and drug candidates it advanced during its operation.